Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 23;46(4):354-362.
doi: 10.14744/cpr.2024.98113. eCollection 2024 Jul.

Investigation of Patients Receiving Ceftazidime-Avibactam (CZA) in an Intensive Care Unit: A Retrospective Study from a Tertiary Hospital

Korhan Kollu  1 , Mikail Dag  2 , Mahmut Sami Ince  1 , Dursun Elmas  1 , Sule Ozdemir Armagan  3 , Muhammet Cemal Kizilarslanoglu  4
Affiliations

Investigation of Patients Receiving Ceftazidime-Avibactam (CZA) in an Intensive Care Unit: A Retrospective Study from a Tertiary Hospital

Korhan Kollu et al. J Clin Pract Res. .

Abstract

Objective: This study aimed to examine the clinical characteristics and prognosis of patients receiving ceftazidime-avibactam (CZA) treatment in an intensive care unit (ICU).

Materials and methods: This observational, cross-sectional study was conducted with patients hospitalized in the ICU between June 2021 and April 2023. Among 1,900 patients, a total of 65 were identified to have received CZA treatment. All patients receiving this treatment were included in the study. We recorded patients' demographic data and comorbid diseases. We also investigated clinical outcomes in the ICU, such as sepsis, the requirement for mechanical ventilation (MV), mortality rates, and clinical features regarding infections.

Results: Of the 65 patients, 69.2% were male, with an average age of 65±15 years. The overall mortality rate was 70.8%. The most common type of infection and the most frequently isolated pathogen were pneumonia (61.5%) and Klebsiella pneumoniae (73.8%), respectively. Deceased patients had clinically poorer scores on the Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II (APACHE-II), and Sequential Organ Failure Assessment (SOFA) than survivors (p=0.006, p<0.001 and p<0.001, respectively). The rate of colistin exposure before CZA treatment was higher among dying patients (p=0.036). Multiple regression analyses indicated that factors independently associated with ICU mortality were the need for mechanical ventilation support [Odds ratio (OR): 15.155; p=0.023), development of septic shock (OR: 8.558; p=0.017), and APACHE-II score (OR: 1.146; p=0.045).

Conclusion: Our findings suggest that the development of septic shock, the requirement for mechanical ventilation (MV), and high APACHE-II and Sequential Organ Failure Assessment (SOFA) scores, and low GCS scores may be indicators of poor prognosis for patients requiring CZA.

Keywords: Carbapenem-resistant; ceftazidime-avibactam; gram-negative bacteria; intensive care unit.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflict of interest to declare.

References

    1. Pitout JD, Nordmann P, Poirel L. Carbapenemase-Producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59(10):5873–84. - PMC - PubMed
    1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. [Accessed Jul 22, 2024]. Available from:URL:https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-... .
    1. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae:clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501–12. - PubMed
    1. Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12(10):570–84. - PubMed
    1. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant enterobacteriaceae:an update on therapeutic options. Front Microbiol. 2019;10:80. - PMC - PubMed

LinkOut - more resources